Rexahn Pharmaceuticals Company Profile (NYSEMKT:RNN)

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals logoRexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSEMKT
  • Symbol: RNN
  • CUSIP:
Key Metrics:
  • Previous Close: $0.24
  • 50 Day Moving Average: $0.1932
  • 200 Day Moving Average: $0.1957
  • 52-Week Range: $0.13 - $0.39
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.38
  • P/E Growth: 0.0000
  • Market Cap: $56.47M
  • Outstanding Shares: 237,368,000
  • Beta: 0.14
Additional Links:
Companies Related to Rexahn Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Rexahn Pharmaceuticals (NYSEMKT:RNN) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.38

Analysts' Ratings History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Show:
DateFirmActionRatingPrice TargetDetails
1/24/2017FBR & CoReiterated RatingOutperformView Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$1.75View Rating Details
8/14/2015MLV & Co.Reiterated RatingBuy$1.25View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
8/8/2016Q216($0.02)($0.01)ViewN/AView Earnings Details
5/9/2016Q116($0.02)($0.02)ViewN/AView Earnings Details
11/3/2015Q315($0.03)($0.02)ViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.02)ViewN/AView Earnings Details
4/6/2015($0.03)($0.01)ViewN/AView Earnings Details
3/17/2015($0.02)($0.02)ViewN/AView Earnings Details
11/14/2014($0.03)($0.02)ViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.02)ViewN/AView Earnings Details
3/25/2014($0.06)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Current Year EPS Consensus Estimate: $-0.0700 EPS
Next Year EPS Consensus Estimate: $-0.1000 EPS

Dividends

Dividend History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/12/2015Chang Ho AhnDirectorSell314,656$0.91$286,336.96View SEC Filing  
1/12/2015Tae Heum JeongCFOSell317,272$0.91$288,717.52View SEC Filing  
6/12/2014Chang Ho AhnDirectorSell136,193$0.99$134,831.07View SEC Filing  
9/9/2013Tae Heum JeongCFOSell71,139$0.46$32,723.94View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Rexahn Pharmaceuticals (NYSEMKT:RNN)
DateHeadline
News IconTwo Stable Stocks: Opko Health, Inc. (NASDAQ:OPK), Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) - The Newburgh Press (NYSEMKT:RNN)
newburghpress.com - February 25 at 2:10 AM
News IconLooking at the Levels for Rexahn Pharmaceuticals Inc (RNN) - The Standard (NYSEMKT:RNN)
6milestandard.com - February 25 at 2:10 AM
News IconStock in Focus: Rexahn Pharmaceuticals, Inc. (AMEX:RNN) - SKV News (NYSEMKT:RNN)
skvnews.com - February 25 at 2:10 AM
News IconTechnical Roundup On Two Stocks Rexahn Pharmaceuticals, Inc. (RNN), Amicus Therapeutics, Inc. (FOLD) - Post Analyst (NYSEMKT:RNN)
postanalyst.com - February 25 at 2:10 AM
smarteranalyst.com logoRexahn Pharmaceuticals, Inc. (RNN) Initiates Clinical Trial to ... - Smarter Analyst (NYSEMKT:RNN)
www.smarteranalyst.com - February 24 at 8:02 AM
News IconRexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin in Patients with Metastatic Triple Negative Breast Cancer (NYSEMKT:RNN)
www.pressreleasepoint.com - February 24 at 12:44 AM
News IconRexahn Pharmaceuticals, Inc. (:RNN) Dipping Lower Ahead of the Market Open (NYSEMKT:RNN)
www.graffiotech.com - February 23 at 7:43 PM
finance.yahoo.com logoRexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer (NYSEMKT:RNN)
finance.yahoo.com - February 23 at 7:43 PM
News IconStocks for your portfolio – Exelon Corporation (NYSE:EXC), Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) - Wall Street Times (press release) (NYSEMKT:RNN)
www.wallstreetnews24.com - February 23 at 8:23 AM
News IconEarnings Guidance on Rexahn Pharmaceuticals, Inc.(RNN ... - Energy Index (NYSEMKT:RNN)
www.energyindexwatch.com - February 23 at 8:23 AM
News IconWhich insiders are selling Rexahn Pharmaceuticals, Inc. (RNN)? - Post Analyst (NYSEMKT:RNN)
postanalyst.com - February 22 at 7:44 PM
News IconRexahn Pharmaceuticals Inc RNN Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NYSEMKT:RNN)
www.bioportfolio.com - February 22 at 7:44 PM
News IconStock Price of Rexahn Pharmaceuticals, Inc. (RNN) Increases 22.74% - Money Flow Index & Trends (NYSEMKT:RNN)
www.moneyflowtrends.com - February 21 at 5:18 PM
News IconWhat are Analyst's Indicators for Rexahn Pharmaceuticals, Inc. (RNN), Corbus Pharmaceuticals Holdings, Inc. (CRBP) - The USA Commerce (NYSEMKT:RNN)
www.theusacommerce.com - February 21 at 5:18 PM
News IconLouis Tomlinson and Eleanor Calder 'rekindle romance two years after split' (NYSEMKT:RNN)
ekosvoice.com - February 19 at 9:08 AM
News IconTop Institutional Investors That Own Rexahn Pharmaceuticals, Inc. (RNN) - Post Analyst (NYSEMKT:RNN)
postanalyst.com - February 18 at 6:39 PM
News IconThe Charts For Rexahn Pharmaceuticals, Inc. (RNN) Is Speaking Volumes Today - NY Stock News (NYSEMKT:RNN)
nystocknews.com - February 17 at 7:51 PM
News IconStock Price of Rexahn Pharmaceuticals, Inc. (RNN) Increases 19.69% (NYSEMKT:RNN)
hypelee.com - February 16 at 7:14 PM
News IconRexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Insider Transactions Are in the Air (NYSEMKT:RNN)
brassale.net - February 16 at 7:14 PM
News IconStock Hovering Above The Trend line: Nice Momentum for Rexahn Pharmaceuticals, Inc. (:RNN) - Winfield Review (NYSEMKT:RNN)
winfieldreview.com - February 15 at 1:07 AM
News Icon10 institutional investors are raising stakes in Rexahn Pharmaceuticals, Inc. (RNN) - Post Analyst (NYSEMKT:RNN)
postanalyst.com - February 15 at 1:07 AM
News IconOverbuying Stock in the Spotlight: Rexahn Pharmaceuticals, Inc ... - Post Registrar (NYSEMKT:RNN)
postregistrar.com - February 15 at 1:07 AM
News IconA Technical Look At 2 Stocks: Plug Power Inc. (PLUG), Rexahn Pharmaceuticals, Inc. (RNN) - Post Analyst (NYSEMKT:RNN)
postanalyst.com - February 14 at 6:02 AM
News IconAnalyst PT & Stock Review on Rexahn Pharmaceuticals, Inc. (:RNN) - Rockville Register (NYSEMKT:RNN)
rockvilleregister.com - February 14 at 6:02 AM
News IconA Cheap Battery That Can Store Renewable Energy and Last a Decade (NYSEMKT:RNN)
ibusinesslines.com - February 14 at 6:02 AM
News IconRichard Panik with three points during win Saturday (NYSEMKT:RNN)
latribunadecanarias.com - February 14 at 6:02 AM
News IconThe Way Wall Street Experts See Rexahn Pharmaceuticals, Inc. (RNN) - Post Analyst (NYSEMKT:RNN)
postanalyst.com - February 13 at 8:45 AM
News IconForward Earnings Estimate of Rexahn Pharmaceuticals, Inc.(RNN ... - Highland Mirror (NYSEMKT:RNN)
www.highlandmirror.com - February 10 at 11:01 PM
finance.yahoo.com logoRexahn Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference (NYSEMKT:RNN)
finance.yahoo.com - February 6 at 7:42 PM
News IconBrokers Add To Their Ratings On Rexahn Pharmaceuticals, Inc. (RNN) - NewsDen (NYSEMKT:RNN)
newsden.net - February 4 at 4:22 AM
News IconOn the Hunt For the Next Wonder Stock: Penny Stock Rexahn Pharmaceuticals, Inc. (:RNN) - Nelson Research (NYSEMKT:RNN)
nelsonobserver.com - February 1 at 11:56 PM
News IconStock Dragging Lower Heading Into The Open: Rexahn Pharmaceuticals, Inc. (:RNN) - Aiken Advocate (NYSEMKT:RNN)
aikenadvocate.com - February 1 at 11:56 PM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Rexahn Pharmaceuticals, Inc. (:RNN) - Nelson Research (NYSEMKT:RNN)
nelsonobserver.com - January 31 at 10:02 PM
News IconInvestor Focus on Technical Levels for Rexahn Pharmaceuticals Inc. (RNN) - Sherwood Daily (NYSEMKT:RNN)
sherwooddaily.com - January 30 at 8:24 PM
News IconIs This Stock Capable of a Bull Run: Rexahn Pharmaceuticals, Inc. (:RNN) - Nelson Research (NYSEMKT:RNN)
nelsonobserver.com - January 30 at 8:24 PM
News IconRexahn Pharmaceuticals, Inc. (AMEX:RNN) Sale Analysis - The Newburgh Press (NYSEMKT:RNN)
newburghpress.com - January 26 at 3:51 AM
News IconLooking at Moving Averages for Rexahn Pharmaceuticals Inc. (RNN) - Sherwood Daily (NYSEMKT:RNN)
sherwooddaily.com - January 24 at 8:06 AM
streetinsider.com logoRexahn Pharma (RNN): Niche in Pancreatic Cancer Looks ... - StreetInsider.com (NYSEMKT:RNN)
www.streetinsider.com - January 24 at 8:06 AM
News IconRexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer (NYSEMKT:RNN)
www.drugs.com - January 23 at 12:22 AM
News IconPrepping for a Big Move? Share Update on Rexahn Pharmaceuticals, Inc. (:RNN) - Prospect Journal (NYSEMKT:RNN)
prospectjournal.com - January 21 at 4:00 AM
News IconActivity Riding High as Traders Make Moves on Rexahn Pharmaceuticals, Inc. (:RNN) - Wall Street Beacon (NYSEMKT:RNN)
wsbeacon.com - January 21 at 4:00 AM
smarteranalyst.com logoStock Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc ... - Smarter Analyst (NYSEMKT:RNN)
www.smarteranalyst.com - January 21 at 4:00 AM
streetinsider.com logoRexahn Pharma (RNN) Presents Update of Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at ASCO (NYSEMKT:RNN)
www.streetinsider.com - January 20 at 10:58 PM
us.rd.yahoo.com logoRexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium (NYSEMKT:RNN)
us.rd.yahoo.com - January 20 at 10:58 PM
us.rd.yahoo.com logo9:01 am Rexahn Pharmaceuticals updates on Phase IIa trial of RX-3117 in metastatic pancreatic cancer at ASCO Gastrointestinal Cancers Symposium (NYSEMKT:RNN)
us.rd.yahoo.com - January 20 at 10:58 PM
News IconRexahn Pharmaceuticals, Inc. (NYSEMKT:RNN):Brokerage Firm Rating Analysis - Highland Mirror (NYSEMKT:RNN)
www.highlandmirror.com - January 20 at 6:32 AM
News IconSpot-check on CCI and RSI for Rexahn Pharmaceuticals Inc. (RNN) - Sherwood Daily (NYSEMKT:RNN)
sherwooddaily.com - January 17 at 7:57 PM
News IconAt the Focal Point, Checking in on Rexahn Pharmaceuticals, Inc ... - Prospect Journal (NYSEMKT:RNN)
prospectjournal.com - January 17 at 7:57 PM
News IconRexahn Pharmaceuticals, Inc. (RNN) : Checking the Chart - The USA Commerce (NYSEMKT:RNN)
theusacommerce.com - January 16 at 6:41 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Rexahn ... - Wall Street Beacon (NYSEMKT:RNN)
wsbeacon.com - January 15 at 8:36 AM

Social

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "RNN."

Where is Rexahn Pharmaceuticals' stock going? Where will Rexahn Pharmaceuticals' stock price be in 2017?

2 brokers have issued 12-month target prices for Rexahn Pharmaceuticals' stock. Their forecasts range from $1.75 to $3.00. On average, they expect Rexahn Pharmaceuticals' share price to reach $2.38 in the next twelve months.

When will Rexahn Pharmaceuticals announce their earnings?

Rexahn Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Rexahn Pharmaceuticals stock?

Rexahn Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.06%).

Who bought Rexahn Pharmaceuticals stock? Who is buying Rexahn Pharmaceuticals stock?

Rexahn Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy Rexahn Pharmaceuticals stock?

Shares of Rexahn Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Rexahn Pharmaceuticals stock cost?

One share of Rexahn Pharmaceuticals stock can currently be purchased for approximately $0.24.


Last Updated on 2/25/2017 by MarketBeat.com Staff